Recombinant Hirudin Medicine Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Dosage Type ( 12000 ATU / mg, 16000 ATU / mg, Others ); Disease Indication ( Heparin-Induced Thrombocytopenia, Unstable Angina, Tumors, Others ) and Geography

Report Code: TIPRE00019586 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Recombinant hirudin is a potent thrombin inhibitor originally derived from the medicinal leech. Hirudin acts directly on thrombin rather than through other clotting factors. The mechanism of Hirudin-thrombin appears to be unique. The conversion of fibrinogen into fibrin by the serine protease enzyme thrombin is a major event in the final stages of blood coagulation.

MARKET DYNAMICS

The recombinant hirudin medicine market is driving due to the factors such as increasing number of patients suffering from trauma and rising number of thrombin based diseases. In addition, rising number of healthcare facilities in emerging economies are likely to offer growth opportunities for market players.

MARKET SCOPE

The "Recombinant Hirudin Medicine Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of recombinant hirudin medicine market with detailed market segmentation by dosage type and disease indication. The recombinant hirudin medicine market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in recombinant hirudin medicine market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The recombinant hirudin medicine market is segmented on the basis of dosage type and disease indication. Based on dosage type, the market is segmented into 12000 ATU / mg, 16000 ATU / mg, and others. On the basis of disease indication, the market is segmented into heparin-induced thrombocytopenia, unstable angina, tumors, others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the recombinant hirudin medicine market based on various segments. It also provides market size and forecast estimates from year 2020 to2028with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The recombinant hirudin medicine market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting recombinant hirudin medicine market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the recombinant hirudin medicine market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the recombinant hirudin medicine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from recombinant hirudin medicine market are anticipated to have lucrative growth opportunities in the future with the rising demand for recombinant hirudin medicine in the global market. Below mentioned is the list of few companies engaged in the recombinant hirudin medicine market.

The report also includes the profiles of key players in recombinant hirudin medicine market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.

  •  Abbott
  •  Pfizer, Inc.
  •  The Medicines Company
  •  Teva Pharmaceutical Ltd.
  •  Pentapharm
  •  PrimeGene
  •  Aniara Diagnostica
  •  Bioassay Technology Laboratory
  •  Novus Biologicals
  •  Sigma Aldrich (Merck KGaA)

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Recombinant Hirudin Medicine Market - By Dosage Type
1.3.2 Recombinant Hirudin Medicine Market - By Disease Indication
1.3.3 Recombinant Hirudin Medicine Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RECOMBINANT HIRUDIN MEDICINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RECOMBINANT HIRUDIN MEDICINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RECOMBINANT HIRUDIN MEDICINE MARKET - GLOBAL MARKET ANALYSIS
6.1. RECOMBINANT HIRUDIN MEDICINE - GLOBAL MARKET OVERVIEW
6.2. RECOMBINANT HIRUDIN MEDICINE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. RECOMBINANT HIRUDIN MEDICINE MARKET - REVENUE AND FORECASTS TO 2028 - DOSAGE TYPE
7.1. OVERVIEW
7.2. DOSAGE TYPE MARKET FORECASTS AND ANALYSIS
7.3. 12000 ATU / MG
7.3.1. Overview
7.3.2. 12000 ATU / mg Market Forecast and Analysis
7.4. 16000 ATU / MG
7.4.1. Overview
7.4.2. 16000 ATU / mg Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. RECOMBINANT HIRUDIN MEDICINE MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. HEPARIN-INDUCED THROMBOCYTOPENIA
8.3.1. Overview
8.3.2. Heparin-Induced Thrombocytopenia Market Forecast and Analysis
8.4. UNSTABLE ANGINA
8.4.1. Overview
8.4.2. Unstable Angina Market Forecast and Analysis
8.5. TUMORS
8.5.1. Overview
8.5.2. Tumors Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. RECOMBINANT HIRUDIN MEDICINE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Recombinant Hirudin Medicine Market Overview
9.1.2 North America Recombinant Hirudin Medicine Market Forecasts and Analysis
9.1.3 North America Recombinant Hirudin Medicine Market Forecasts and Analysis - By Dosage Type
9.1.4 North America Recombinant Hirudin Medicine Market Forecasts and Analysis - By Disease Indication
9.1.5 North America Recombinant Hirudin Medicine Market Forecasts and Analysis - By Countries
9.1.5.1 United States Recombinant Hirudin Medicine Market
9.1.5.1.1 United States Recombinant Hirudin Medicine Market by Dosage Type
9.1.5.1.2 United States Recombinant Hirudin Medicine Market by Disease Indication
9.1.5.2 Canada Recombinant Hirudin Medicine Market
9.1.5.2.1 Canada Recombinant Hirudin Medicine Market by Dosage Type
9.1.5.2.2 Canada Recombinant Hirudin Medicine Market by Disease Indication
9.1.5.3 Mexico Recombinant Hirudin Medicine Market
9.1.5.3.1 Mexico Recombinant Hirudin Medicine Market by Dosage Type
9.1.5.3.2 Mexico Recombinant Hirudin Medicine Market by Disease Indication
9.2. EUROPE
9.2.1 Europe Recombinant Hirudin Medicine Market Overview
9.2.2 Europe Recombinant Hirudin Medicine Market Forecasts and Analysis
9.2.3 Europe Recombinant Hirudin Medicine Market Forecasts and Analysis - By Dosage Type
9.2.4 Europe Recombinant Hirudin Medicine Market Forecasts and Analysis - By Disease Indication
9.2.5 Europe Recombinant Hirudin Medicine Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Recombinant Hirudin Medicine Market
9.2.5.1.1 Germany Recombinant Hirudin Medicine Market by Dosage Type
9.2.5.1.2 Germany Recombinant Hirudin Medicine Market by Disease Indication
9.2.5.2 France Recombinant Hirudin Medicine Market
9.2.5.2.1 France Recombinant Hirudin Medicine Market by Dosage Type
9.2.5.2.2 France Recombinant Hirudin Medicine Market by Disease Indication
9.2.5.3 Italy Recombinant Hirudin Medicine Market
9.2.5.3.1 Italy Recombinant Hirudin Medicine Market by Dosage Type
9.2.5.3.2 Italy Recombinant Hirudin Medicine Market by Disease Indication
9.2.5.4 Spain Recombinant Hirudin Medicine Market
9.2.5.4.1 Spain Recombinant Hirudin Medicine Market by Dosage Type
9.2.5.4.2 Spain Recombinant Hirudin Medicine Market by Disease Indication
9.2.5.5 United Kingdom Recombinant Hirudin Medicine Market
9.2.5.5.1 United Kingdom Recombinant Hirudin Medicine Market by Dosage Type
9.2.5.5.2 United Kingdom Recombinant Hirudin Medicine Market by Disease Indication
9.2.5.6 Rest of Europe Recombinant Hirudin Medicine Market
9.2.5.6.1 Rest of Europe Recombinant Hirudin Medicine Market by Dosage Type
9.2.5.6.2 Rest of Europe Recombinant Hirudin Medicine Market by Disease Indication
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Recombinant Hirudin Medicine Market Overview
9.3.2 Asia-Pacific Recombinant Hirudin Medicine Market Forecasts and Analysis
9.3.3 Asia-Pacific Recombinant Hirudin Medicine Market Forecasts and Analysis - By Dosage Type
9.3.4 Asia-Pacific Recombinant Hirudin Medicine Market Forecasts and Analysis - By Disease Indication
9.3.5 Asia-Pacific Recombinant Hirudin Medicine Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Recombinant Hirudin Medicine Market
9.3.5.1.1 Australia Recombinant Hirudin Medicine Market by Dosage Type
9.3.5.1.2 Australia Recombinant Hirudin Medicine Market by Disease Indication
9.3.5.2 China Recombinant Hirudin Medicine Market
9.3.5.2.1 China Recombinant Hirudin Medicine Market by Dosage Type
9.3.5.2.2 China Recombinant Hirudin Medicine Market by Disease Indication
9.3.5.3 India Recombinant Hirudin Medicine Market
9.3.5.3.1 India Recombinant Hirudin Medicine Market by Dosage Type
9.3.5.3.2 India Recombinant Hirudin Medicine Market by Disease Indication
9.3.5.4 Japan Recombinant Hirudin Medicine Market
9.3.5.4.1 Japan Recombinant Hirudin Medicine Market by Dosage Type
9.3.5.4.2 Japan Recombinant Hirudin Medicine Market by Disease Indication
9.3.5.5 South Korea Recombinant Hirudin Medicine Market
9.3.5.5.1 South Korea Recombinant Hirudin Medicine Market by Dosage Type
9.3.5.5.2 South Korea Recombinant Hirudin Medicine Market by Disease Indication
9.3.5.6 Rest of Asia-Pacific Recombinant Hirudin Medicine Market
9.3.5.6.1 Rest of Asia-Pacific Recombinant Hirudin Medicine Market by Dosage Type
9.3.5.6.2 Rest of Asia-Pacific Recombinant Hirudin Medicine Market by Disease Indication
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Recombinant Hirudin Medicine Market Overview
9.4.2 Middle East and Africa Recombinant Hirudin Medicine Market Forecasts and Analysis
9.4.3 Middle East and Africa Recombinant Hirudin Medicine Market Forecasts and Analysis - By Dosage Type
9.4.4 Middle East and Africa Recombinant Hirudin Medicine Market Forecasts and Analysis - By Disease Indication
9.4.5 Middle East and Africa Recombinant Hirudin Medicine Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Recombinant Hirudin Medicine Market
9.4.5.1.1 South Africa Recombinant Hirudin Medicine Market by Dosage Type
9.4.5.1.2 South Africa Recombinant Hirudin Medicine Market by Disease Indication
9.4.5.2 Saudi Arabia Recombinant Hirudin Medicine Market
9.4.5.2.1 Saudi Arabia Recombinant Hirudin Medicine Market by Dosage Type
9.4.5.2.2 Saudi Arabia Recombinant Hirudin Medicine Market by Disease Indication
9.4.5.3 U.A.E Recombinant Hirudin Medicine Market
9.4.5.3.1 U.A.E Recombinant Hirudin Medicine Market by Dosage Type
9.4.5.3.2 U.A.E Recombinant Hirudin Medicine Market by Disease Indication
9.4.5.4 Rest of Middle East and Africa Recombinant Hirudin Medicine Market
9.4.5.4.1 Rest of Middle East and Africa Recombinant Hirudin Medicine Market by Dosage Type
9.4.5.4.2 Rest of Middle East and Africa Recombinant Hirudin Medicine Market by Disease Indication
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Recombinant Hirudin Medicine Market Overview
9.5.2 South and Central America Recombinant Hirudin Medicine Market Forecasts and Analysis
9.5.3 South and Central America Recombinant Hirudin Medicine Market Forecasts and Analysis - By Dosage Type
9.5.4 South and Central America Recombinant Hirudin Medicine Market Forecasts and Analysis - By Disease Indication
9.5.5 South and Central America Recombinant Hirudin Medicine Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Recombinant Hirudin Medicine Market
9.5.5.1.1 Brazil Recombinant Hirudin Medicine Market by Dosage Type
9.5.5.1.2 Brazil Recombinant Hirudin Medicine Market by Disease Indication
9.5.5.2 Argentina Recombinant Hirudin Medicine Market
9.5.5.2.1 Argentina Recombinant Hirudin Medicine Market by Dosage Type
9.5.5.2.2 Argentina Recombinant Hirudin Medicine Market by Disease Indication
9.5.5.3 Rest of South and Central America Recombinant Hirudin Medicine Market
9.5.5.3.1 Rest of South and Central America Recombinant Hirudin Medicine Market by Dosage Type
9.5.5.3.2 Rest of South and Central America Recombinant Hirudin Medicine Market by Disease Indication
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RECOMBINANT HIRUDIN MEDICINE MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RECOMBINANT HIRUDIN MEDICINE MARKET, KEY COMPANY PROFILES
12.1. ABBOTT
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. THE MEDICINES COMPANY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TEVA PHARMACEUTICAL LTD.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PENTAPHARM
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PRIMEGENE
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ANIARA DIAGNOSTICA
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BIOASSAY TECHNOLOGY LABORATORY
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVUS BIOLOGICALS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SIGMA ALDRICH (MERCK KGAA)
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Abbott
2. Pfizer, Inc.
3. The Medicines Company
4. Teva Pharmaceutical Ltd.
5. Pentapharm
6. PrimeGene
7. Aniara Diagnostica
8. Bioassay Technology Laboratory
9. Novus Biologicals
Sigma Aldrich (Merck KGaA)
TIPRE00019586
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking